Open Water Internet, Inc.

Openwater occupies an unusual position between medical imaging, neuromodulation, and wearable diagnostics. Its closest competitive reference points include Butterfly Network in portable ultrasound, Insightec in focused-ultrasound therapy, and Kernel in wearable neurotechnology, although the companies address different combinations of measurement and treatment. Openwater’s differentiation is its attempt to combine Open-Motion measurement with Open-LIFU intervention in a closed-loop platform, rather than selling a single imaging or therapeutic modality. The company also emphasizes open-source hardware, firmware, and software, which could support third-party experimentation and lower development costs compared with tightly controlled device ecosystems. Its technology thesis uses optical sensing, small-pixel displays, holographic imaging, and focused ultrasound to pursue MRI-like resolution or targeted tissue modulation in more portable form factors. However, the competitive position remains research-stage: Open-Motion is not FDA-evaluated, and Open-LIFU is described as investigational. The company therefore competes today primarily for research partnerships, clinical validation, and specialist adoption rather than mature hospital procurement budgets.

Openwater’s trajectory shows a progression from foundational financing into platform validation and research deployment. The company raised $22 million in its Series A on Dec 10, 2018 and a further $54 million Venture Round on Aug 22, 2024, bringing recorded funding to $76 million across three rounds; the Seed round’s amount is undisclosed. Its product strategy has broadened from a general cellular-level medical-technology thesis into two identifiable platforms: Open-Motion for optical measurement of blood flow, blood volume, oxygenation, and micro-motion, and Open-LIFU for low-intensity focused-ultrasound neuromodulation and tissue modulation. The 2025 deployments at MIT Lincoln Laboratory and the University of Birmingham marked an important shift toward external research use. The January 2026 TIESA collaboration extended that work into mental-health research. Aaron Timm’s appointment as CEO in March 2025 adds an operating executive while Mary Lou Jepsen remains chairperson. The next major inflection points are likely regulatory validation, reproducible clinical evidence, manufacturing scale, and conversion of investigational deployments into approved products.